Pfizer's Setbacks With Paxlovid Are Mounting -- Should Investors Be Concerned?

Pfizer's Setbacks With Paxlovid Are Mounting -- Should Investors Be Concerned?

Source: 
Motley Fool
snippet: 
  • Paxlovid sales weren't as high as expected.
  • The drug's total addressable market may not be as large as investors initially hoped.
  • Emerging concerns about rebounding COVID-19 symptoms after treatment are not reassuring.